Tariffs

(WASHINGTON, D.C.) — The Consumer Healthcare Products Association (CHPA) released the following statement today after submitting comments to the U.S. Department of Commerce’s Bureau of Industry and Security (BIS) regarding its Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients:

CHPA believes FDA should continuously evaluate food colors for safety using a transparent science-based approach. Policy changes should be science based and realistic about implementation timelines and the complex manufacturing realities involved.

(WASHINGTON, D.C.) — The Consumer Healthcare Products Association (CHPA) today responded to an announcement from the Department of Commerce this week regarding the initiation of a Section 232 investigation into the national security implications of pharmaceutical imports, including finished drug products, active pharmaceutical ingredients (APIs), and other critical materials:

(WASHINGTON, D.C.) – Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville released the below statement following President Trump imposing a 25% tariff on imports from Mexico and Canada, which were originally set to take effect Tuesday, Feb. 4 at 12:01 a.m. EST. As of this morning, the Trump Administration has agreed to pause sweeping tariffs on Mexico for one month while the two sides work on an agreement.